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ABSTRACT 
We recently showed that upregulation of a key oncogene FOXM1 precedes head and neck squamous 
cell carcinoma (HNSCC) malignancy. Furthermore, we also identified a centrosomal protein CEP55 
and a DNA helicase/putative stem cell marker HELLS, which are both downstream targets of FOXM1. 
In this study, we have investigated the expression profiles of CEP55 and HELLS using 
immunohistochemistry and quantified by digital densitometry in a tissue panel (20 samples) consisting 
of normal oral mucosa, dysplasias, HNSCC and lymph node metastasis (LnMet) samples. 
Furthermore, we corroborated our findings using absolute real-time PCR (qPCR) on a panel of 12 
primary normal human oral keratinocytes, 5 dysplasia and 10 HNSCC cell lines. Finally, we validated 
our study using bioinformatics microarray analysis on an independent HNSCC patient cohort (4 
normal and 16 tumours). In normal oral mucosa, CEP55 protein was detected at very low level within 
the upper differentiated layers. In contrast, CEP55 was highly expressed in oral dysplasia whereas 
only moderate expression was detected in HNSCC and LnMet. Low level of HELLS expression was 
detected in the basal cell layer of the normal oral mucosa, moderate level was seen in dysplasia and 
high levels in both HNSCC and LnMet. These expression patterns were consistent with both qPCR 
data from the cell line panel and microarray data analysis of TNM-stage defined HNSCC samples 
confirming the progressive expression pattern of CEP55 and HELLS. To our knowledge, this is the 
first pilot study demonstrating that both CEP55 and HELLS mRNA and protein expression positively 
correlate with pre-malignancy and HNSCC progression. This study provides strong evidence that 
CEP55 and HELLS may be used in conjunction with FOXM1 as a biomarker set for early cancer 
detection and indicators of malignant conversion and progression. 
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INTRODUCTION 
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide and it 
has higher death rates than cancers of the colon, breast, vulva or melanoma.1 In the UK, over 4700 
new cases are reported annually. Its impact on health services, the patients, their families and society 
in general is financially crippling because of the cost of treatment and the effect on the patients’ 
cosmetic appearance, speech and eating. In recent years, there has been evidence of an increasing 
rate of HNSCC incidence in several European countries probably due to the changing trends of 
alcohol and tobacco consumption and exposure, especially in females.2 Because of late tumour 
detection coupled with high recurrence rate after treatment, the 5-year survival of patients remains 
poor (average 50%, depending on clinical stage at diagnosis).1 This supports the need for better 
screening and diagnostic interventions to improve early detection of HNSCC. 
The human transcription factor FOXM1 gene consists of 10 exons located on the 12p13.3 
chromosomal band (telomeric position). Two exons, named exons Va and VIIa, also referred to as 
exon A1 (or rat exon 6) and A2 respectively, are alternatively spliced.3, 4 FOXM1 has a role in cell 
cycle, DNA repair and maintenance of genomic stability.5 We were the first to establish a link between 
FOXM1 and oncogenesis when we showed that FOXM1 was upregulated in basal cell carcinoma,3 
the most common type of cancer in Caucasians worldwide. Subsequent studies of FOXM1 in many 
different solid human cancer types confirmed its pivotal role in oncogenesis.5, 6 We have recently 
reported that transcriptional upregulation of FOXM1 precedes malignancy in a number of solid human 
cancer types including oral, oesophagus, lung, breast, kidney, bladder and uterus.7 It has been shown 
that FOXM1 interacts with the human papilloma virus (HPV) 16 E7 protein8 and that HPV16 E6/E7 
has been implicated in HNSCC.9 It is likely that HPV may play a role in HPV-positive HNSCC through 
FOXM1 activation. However, it has been shown that the frequency of HNSCCs that have integrated 
HPV and express high levels E7 is only in the region of 4-16%.10, 11  
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We have recently shown that aberrant upregulation of FOXM1 serves as a first oncogenic hit by 
destabilising the genome and subsequent activation of downstream targets which regulates 
cytokinesis (CEP55, centrosomal protein 55kDa)12-14 and epigenetic/stem-cell factor re-programming 
(HELLS, helicase lymphoid specific)15-18 leading to malignant transformation (anchorage-independent 
growth) of a premalignant oral keratinocyte line (SVpgC2a).7 However, the protein expression profiles 
of CEP55 and HELLS during HNSCC progression have not been described. In this study, we have 
characterised the expression patterns of CEP55 and HELLS using immunohistochemistry and digital 
densitometry to quantify their protein levels in an HNSCC progression tissue panel consisting of 
normal oral mucosa, dysplasias, HNSCC and lymph node metastasis (LnMet). We have 
complemented these findings using absolute real-time reverse transcription PCR (qPCR) on a panel 
of primary normal human oral keratinocytes, dysplasia and HNSCC cell lines. The data suggest that 
CEP55 and HELLS in combination with FOXM1 are early markers of cancer detection and they are 
also indicators of malignant conversion and progression. 
 
MATERIALS & METHODS 
Clinical Samples 
The use of human tissue was approved by the relevant Research Ethics Committees at each 
institution. The present study involved 20 patients’ formalin-fixed paraffin embedded (FFPE) archival 
tissues as previously described.7 
Immunohistochemistry and digital pixel densitometry 
FOXM1 was immunostained with a rabbit polyclonal antibody (K-19; Santa Cruz Biotechnology, 
California, USA) and mouse monoclonal antibodies for both CEP55 (AB57537-100; Abcam plc, 
Cambridge, UK) and HELLS (anti-LSH H-4 SC-46665; Santa Cruz) on paraffin sections as 
described.3, 7, 19 The reaction product was visualised with diaminobenzidine as a chromogenic 
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substrate in FFPE tissue sections. As described previously,7, 20, 21 digital pixel densitometry was 
performed using Adobe Photoshop CS3 (Adobe Systems Incorporated, USA) utilising the Colour 
Range tool for colour-based quantification or Lasso tool for manual selection of epithelial mucosa area 
and subsequent pixel area readout from the Histogram data chart. Whilst we have also used the 
ImageJ program for pixel densitometry and obtained similar results, Photoshop was preferred for its 
accuracy, reproducibility and ease of use. 
Cell culture 
Primary normal human oral keratinocytes (12 different NHOK primary cultures) were cultured in a 
modified version of Keratinocyte SFM (K-SFM, #17005-034 Gibco, Invitrogen) medium22 containing 
0.09 mM CaCl2. K-SFM was supplemented with 25 µg/ml bovine pituitary extract, 0.2 ng/ml EGF 
(#37000-015 Gibco, Invitrogen), and 1% penicillin/streptomycin. Oral premalignant cell lines: 
OKF6/T,23 POE9n,22 DOK,24 D19,7 D20,7 and primary HNSCC derived cell lines: SCC9,25 SCC15,25 
SCC25,25 SqCC/Y1,26 UK1,27 VB6,27 CaLH2,27 CaDec12,27 5PT,27 H35727 were cultured as described 
previously.7 
Real-time absolute quantitative RT-PCR 
Poly-A+ mRNA extraction, reverse transcription and real-time absolute quantitative PCR (qPCR) 
protocols are MIQE compliant28 and were performed as described previously7 using a LightCycler 
LC480 instrument (Roche Diagnostic). Primer sequences for FOXM1B, CEP55, HELLS and two 
stable reference genes (POLR2A and YAP1) were described previously.7 Statistical analysis was 
performed using the GraphPad InStat software (V2.04a, GraphPad Software, San Diego, CA) for 
Student's t-test analysis. 
Bioinformatics analyses of microarray data 
FOXM1, CEP55 and HELLS endogenous mRNA levels were analysed using published microarray 
data in a study using normal oral mucosa and a panel of TNM-staged defined HNSCC tissues29. The 
microarray dataset (GDS1584) was obtained from the NCBI’s Gene Expression Omnibus (GEO) 
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database. The Affymetrix gene reference identification for FOXM1, CEP55 and HELLS are 
202580_x_at, 218542_at and 220085_at, respectively. Gene expression levels were statistically 
analysed using Student’s t-test in Microsoft Excel software. 
 
RESULTS 
Protein Expression patterns of CEP55 and HELLS during HNSCC progression  
In order to validate our previous finding that CEP55 and HELLS are targets of FOXM1, we 
investigated the CEP55 (Fig. 1) and HELLS (Fig. 2) protein expression levels by 
immunohistochemistry on a panel of 5 normal human oral mucosa, 5 oral dysplasia, 5 primary 
HNSCC and 5 LnMet FFPE archival tissues. In normal oral mucosa, very low level of CEP55 
immunostaining was detected in the middle/upper suprabasal layers (Fig. 1A,B - Normal). As the 
staining was restricted only to the keratinised layers we believe that this may be non-specific staining. 
In contrast, intense but heterogeneous nuclear and cytoplasmic CEP55 expression was detected in 
oral dysplasia within the basaloid suprabasal layers (Fig. 1A,B – Dysplasia). Moderately upregulated 
level of cytoplasmic CEP55 protein was detected in HNSCC tissues (Fig. 1A,B – HNSCC). In LnMet, 
CEP55 exhibits a heterogeneous expression pattern with higher cytoplasmis and nuclear protein 
levels detected along the periphery of tumour mass (Fig. 1A,B - LnMet). Digital densitometry was used 
to quantify the levels of CEP55 expression where 6-10 digital images were captured and quantified 
from each tissue specimen. Individual data points for each tissue specimen were plotted as a scatter 
plot (Fig. 1C) and Box-and-Whisker plot (Fig. 1D) to illustrate the distribution pattern of CEP55 protein 
expression across the tissue panel. Mean  SEM analysis plot (Fig. 1E) showed that CEP55 was 
significantly upregulated in dysplasia and HNSCC. The upregulation of CEP55 in LnMet was not 
significant due to tissue heterogeneity. 
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In normal oral mucosa, HELLS nuclear immunostaining was detected strictly within the basal layer of 
the oral mucosa epithelium (Fig. 2A,B - Normal). In oral dysplasia, HELLS nuclear expression was 
moderately upregulated and found throughout the basaloid layers (Fig. 2A,B – Dysplasia). High level 
of nuclear HELLS protein was detected in HNSCC tumour masses (Fig. 2A,B – HNSCC). In LnMet, 
HELLS exhibits a heterogeneous nuclear expression pattern (Fig. 2A,B - LnMet). Individual data 
points for each tissue specimen were plotted as a scatter plot (Fig. 2C) and Box-and-Whisker plot (Fig. 
2D) as described above for CE55 expression. The mean expression  SEM analysis plot (Fig. 2E) 
showed that HELLS was significantly upregulated in all three disease tissues with a progressive trend. 
Correlation of CEP55 and HELLS mRNA expression with FOXM1 
It has been previously established that FOXM1B shows a progressive expression pattern during 
HNSCC progression.7 Since CEP55 and HELLS are downstream targets of FOXM1B, we 
hypothesise that their expression patterns should show a positive correlation with FOXM1B. To test 
this hypothesis, we measured the mRNA expression levels of FOXM1B, CEP55 and HELLS in a 
panel of 12 primary normal human oral keratinocytes, 5 dysplasia (OKF6/T, POE9n, DOK, D19 and 
D20) and 10 primary HNSCC derived keratinocyte cell lines (SCC9, SCC15, SCC25, SqCC/Y1, UK1, 
VB6, CaLH2, CaDec12, 5PT and H357) using absolute qPCR. Both CEP55 (Fig. 3A) and HELLS 
(Fig. 3B) showed good expression correlation with FOXM1B across the panel of cell lines used. 
Bioinformatics microarray analysis of CEP55 and HELLS expression 
To further validate the above findings, we performed bioinformatics analysis on an independent 
HNSCC patient cohort comparing 4 normal oral mucosa and 16 TNM-stage defined HNSCC 
samples.29 The gene expression data of CEP55 and HELLS were extracted from the microarray 
dataset (GDS1584) using the NCBI’s Gene Expression Omnibus online research tool as described 
previously.7 The expression patterns of FOXM1, CEP55 and HELLS all showed similar bell-shaped 
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profile across the different TNM tumour stages (Fig. 1C) with peak expression at early-mid tumour 
stages (T1N2bM0 to T4N2bM0) and decrease expression found in more advance tumour stages 
(T4N2M0 and T4N3M0). Statistical analysis showed that FOXM1 and CEP55 were significantly 
upregulated in the HNSCC (n=16) compared to normal tissues (n=4) (Fig. 3D). The upregulation of 
HELLS expression in HNSCC was not statistically significant due to a greater heterogeneous gene 
expression within the different HNSCC tumour stages. 
 
DISCUSSION 
It is now well established that FOXM1 is a major oncogene in myriad of human cancers including 
HNSCC.7, 30 In our previous study, we identified CEP55 and HELLS as two downstream targets of 
FOXM1.7 Herein, we have provided the first protein expression evidence that both CEP55 and HELLS 
are differentially expressed during tumour progression from dysplasia to HNSCC and LnMet in human 
oral tissues. Both their expression patterns correlated well with that of FOXM1 expression profile 
across a cell line panel containing normal oral keratinocytes, dysplasia and HNSCC derived cells. The 
progressive pattern of gene expression of CEP55 and HELLS was further validated using 
bioinformatics microarray data analysis on an independent cohort of HNSCC study. 
CEP55 is a microtubule-bundling protein that localizes to the mitotic spindle during prometaphase and 
metaphase and to the spindle midzone and the midbody during anaphase and is required for the 
completion of cytokinesis.12-14 Consistent with CEP55 being a direct transcriptional target of FOXM1,7 
both CEP5512 and FOXM131 share organ-specific expression in the testis and thymus of normal adult 
humans. CEP55 is upregulated in hepatocellular carcinoma and its overexpression induces 
anchorage-independent growth, enhanced cell growth at low serum levels and induction of 
tumourigenesis in nude mice.32 Another study showed that CEP55 was overexpressed in lung cancer 
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and is associated with cell migration and invasion.33 Consistent with a role in malignancy, similar to the 
expression of FOXM1,7 we found that CEP55 expression is significantly upregulated in both oral 
dysplasia and HNSCC tissues. Interestingly, a study involving 3 independent breast cancer patient 
cohorts of microarray datasets containing a total of 699 patients revealed that CEP55 and FOXM1 are 
amongst the signature prognostic markers which predict poor breast cancer outcome.34 Another study 
showed that FOXM1 and CEP55 were ranked 3rd and 43rd, respectively, most significant predictor 
genes for poor clinical outcome in 6 different cancer types.35 Consistent with being a potential cancer 
biomarker, CEP55 has been shown to act as a novel breast carcinoma-associated antigen36 which 
has important implications in cancer diagnostic and/or therapeutic interventions. 
Whilst we have previously demonstrated using chromatin-immunoprecipitation that FOXM1 protein 
directly transactivated the promoter of CEP55 to induce gene expression, we find no evidence of a 
FOXM1-binding site on the HELLS promoter, despite showing a strong correlation in gene expression 
between FOXM1 and HELLS.7 Our current data also showed significant correlation in both protein and 
mRNA expression pattern between HELLS and FOXM1 during HNSCC progression. Similar to 
FOXM131 and CEP55,12 HELLS also showed organ-specific expression in the testis and thymus.37 
Nevertheless, because only 1kb of the HELLS promoter region was analysed,7 the FOXM1 binding 
site(s) could be located beyond the HELLS promoter region tested. Further study involving a larger 
promoter region of HELLS is required to establish the basis for HELLS induction by FOXM1. 
HELLS is a member of the SNF2 (Sucrose Non-Fermenter) family of helicase proteins implicated in 
mammalian development and cellular proliferation,16, 38 through chromatin-remodelling and DNA 
methylation.39-42 Whilst deletion of HELLS gene causes developmental retardation, premature ageing 
and cellular senescence,38, 43-45 gene modification or upregulation of HELLS has been implicated in 
various human cancer including leukaemia,37 non-small cell lung cancer,46 breast cancer,47 and 
melanoma.48 HELLS was recently identified as one of the consensus genes expressed in human 
embryonic stem cells.17 Recently, DNA methyltransferase 1 (DNMT1), an interacting partner of 
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HELLS,42 was shown to maintain progenitor function in self-renewing epidermis49 highlighting a role for 
HELLS in progenitor cell maintenance and renewal. Interestingly, in the present study, HELLS 
expression was strictly restricted to the basal layer of the normal mucosa epithelium and that 
upregulation of HELLS was found in the hyperplastic basal and suprabasal layers in oral dysplasia. 
This pattern of HELLS expression appear highly similar to that of FOXM1 immunostaining in basal cell 
carcinomas3 and in HNSCC.7 We therefore speculate that the upregulation of HELLS (and FOXM1) in 
HNSCC may indicate a deregulation of progenitor cell maintenance leading to hyperproliferation and 
tumour development.  
In summary, this study provided the first evidence that a novel set of proliferation-associated genes 
FOXM1, CEP55 and HELLS share progressive expression pattern during the progression of HNSCC.  
The fact that upregulation of these three genes precedes HNSCC malignancy renders them potential 
cancer biomarkers for early detection of malignant conversion. This pilot study would pave way for 
future studies involving more tissue samples for validating their diagnostic potential as biomarkers for 
HNSCC. 
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Figure Legends 
Figure 1. Immunostaining of CEP55 in human normal oral mucosa, dysplasia, HNSCC and lymph 
node metastasis (LnMet). (A) Two representative images for each tissue category are shown here. (B) 
Magnified views of selected regions (dotted boxes) in (A) are shown. (C) Scatter plot of digital pixel 
densitometry data for CEP55 protein immunoreactivity in a panel of 20 oral tissues (n=5 in each 
group) as shown in (A). (D) Box-and-Whisker plot for the same data from (C). (E) Mean analysis of 
data points from (C) *(P<0.05) and **(P<0.01) indicate statistically significant elevation of CEP55 
protein levels when compared to normal oral mucosa tissues. 
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Figure 2. Immunostaining of HELLS in human normal oral mucosa, dysplasia, HNSCC and lymph 
node metastasis (LnMet). (A) Two representative images for each tissue category are shown here. (B) 
Magnified views of selected regions (dotted boxes) in (A) are shown. (C) Scatter plot of digital pixel 
densitometry data for HELLS protein immunoreactivity in a panel of 20 oral tissues (n=5 in each 
group) as shown in (A). (D) Box-and-Whisker plot for the same data from (C). (E) Mean analysis of 
data points from (C) *(P<0.05) and ***(P<0.001) indicate statistically significant elevation of HELLS 
protein levels when compared to normal oral mucosa tissues. 
Figure 3. Gene expression analysis of FOXM1, CEP55 and HELLS in cell line panel and HNSCC 
tissues. (A) A non-linear regression analysis between CEP55 and FOXM1B mRNA expression levels 
determined by absolute qPCR across a cell line panel consisting of 12 normal human oral 
keratinocytes (NHOK), 5 dysplasia and 10 HNSCC cell lines. (B) A non-linear regression analysis 
between HELLS and FOXM1B mRNA expression levels across the same panel of cell lines used in 
(A). (C) Bioinformatics analysis of FOXM1, CEP55 and HELLS gene expression from a microarray 
dataset involving 4 normal oral mucosa and 16 TNM-stage defined HNSCC tissues (GDS158429). (D) 
Mean analysis of FOXM1, CEP55 and HELLS gene expression using the same dataset from (C) 
comparing the normal (n=4) and HNSCC (n=16) samples. *(P<0.05) and **(P<0.01) indicate 
statistically significant gene upregulation in HNSCC when compared to normal oral mucosa tissues. 
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